Silicosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Silicosis}} | {{Silicosis}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}} {{AV}} | ||
==Overview== | ==Overview== | ||
Following diagnosis, secondary prevention is the main approach for the management of patients with silicosis. Secondary prevention measures include avoidance of continued exposure, [[smoking cessation]], routine medical surveillance, and administration of [[influenza]] and [[pneumococcal vaccine|pneumococcal vaccines]].<ref name="pmid22534002">{{cite journal| author=Leung CC, Yu IT, Chen W| title=Silicosis. | journal=Lancet | year= 2012 | volume= 379 | issue= 9830 | pages= 2008-18 | pmid=22534002 | doi=10.1016/S0140-6736(12)60235-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22534002 }} </ref> | Following diagnosis, secondary prevention is the main approach for the management of patients with silicosis. Secondary prevention measures include avoidance of continued exposure, [[smoking cessation]], routine medical surveillance, and administration of [[influenza]] and [[pneumococcal vaccine|pneumococcal vaccines]].<ref name="pmid22534002">{{cite journal| author=Leung CC, Yu IT, Chen W| title=Silicosis. | journal=Lancet | year= 2012 | volume= 379 | issue= 9830 | pages= 2008-18 | pmid=22534002 | doi=10.1016/S0140-6736(12)60235-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22534002 }} </ref> | ||
| Line 18: | Line 19: | ||
===Vaccine Administration=== | ===Vaccine Administration=== | ||
*Patients diagnosed with silicosis should be advised to receive both the [[influenza]] and the [[pneumonoccal vaccine]]. | *Patients diagnosed with silicosis should be advised to receive both the [[influenza]] and the [[pneumonoccal vaccine]]. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 15:38, 8 June 2016
|
Silicosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Silicosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Silicosis secondary prevention |
|
Risk calculators and risk factors for Silicosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
Following diagnosis, secondary prevention is the main approach for the management of patients with silicosis. Secondary prevention measures include avoidance of continued exposure, smoking cessation, routine medical surveillance, and administration of influenza and pneumococcal vaccines.[1]
Secondary Prevention
Avoidance of Continued Exposure
- Avoidance of continued exposure to environments with high concentrations of silica is recommended.
Smoking Cessation
- Smoking cessation is required to prevent further decline in respiratory function.
Routine Medical Surveillance
- Patients should be recommended to routinely monitor the following:
- Chest x-ray
- Spirometry
- Sputum exam with acid fast bacilli (AFB) staining to screen for tuberculosis
Vaccine Administration
- Patients diagnosed with silicosis should be advised to receive both the influenza and the pneumonoccal vaccine.
References
- ↑ Leung CC, Yu IT, Chen W (2012). "Silicosis". Lancet. 379 (9830): 2008–18. doi:10.1016/S0140-6736(12)60235-9. PMID 22534002.